Reduced insulin growth factor I concentrations in iron-overloaded beta thalassaemic patients with normal growth...

Area of Science:

• Pediatric Endocrinology
• Hematology
• Growth Disorders

Background:

• Short stature is a concern in pediatric patients, particularly those with chronic conditions like beta-thalassemia.
• Growth Hormone (GH) and Insulin-like Growth Factor I (IGF-I) are critical regulators of linear growth.
• Understanding the interplay between GH, IGF-I, and short stature in beta-thalassemia is essential for effective treatment.

Purpose of the Study:

• To investigate Growth Hormone (GH) secretion and Insulin-like Growth Factor I (IGF-I) levels in children with beta-thalassemia and short stature.
• To compare these parameters with children suffering from idiopathic short stature (ISS) and healthy controls.
• To explore potential mechanisms behind short stature in beta-thalassemia patients, including GH insensitivity.

Main Methods:

• Study included 92 children (10-15 years): 46 beta-thalassemia (beta-Th) with short stature, 23 with idiopathic short stature (ISS), and 23 healthy controls.
• GH secretion was assessed via stimulation tests.
• IGF-I levels were measured and analyzed across the different groups.

Main Results:

• Low IGF-I was prevalent in beta-thalassemia patients (73.9% with GH deficiency, 56.5% with normal GH secretion).
• Only 8.7% of children with ISS showed low IGF-I.
• Beta-thalassemia patients with normal GH secretion exhibited reduced IGF-I, suggesting potential GH insensitivity or other regulatory issues.

Conclusions:

• Reduced IGF-I in beta-thalassemia patients with short stature, even with normal GH secretion, points to possible GH insensitivity (GHIS).
• Other contributing factors may include neurosecretory dysfunction, low bioactive GH, or altered GH isoform proportions.
• Higher doses of recombinant human GH (rechGH) might be necessary to improve growth velocity in these patients.